Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20) (remove)
Language
- English (20)
Keywords
- multiple myeloma (14)
- CXCR4 (3)
- lenalidomide (3)
- medicine (3)
- molecular imaging (3)
- FDG (2)
- PET (2)
- amplicon sequencing (2)
- amyloidosis (2)
- bone disease (2)
- bortezomib (2)
- deformation (2)
- echocardiography (2)
- ejection fraction (2)
- pomalidomide (2)
- positron emission tomography (2)
- prognosis (2)
- stem-cell transplantation (2)
- theranostics (2)
- 18FDG-PET/CT (1)
- AKT-signaling (1)
- Antibodies (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- Hepatitis B virus reactivation (1)
- KRAS (1)
- MEK/ERK-signaling (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- PET/CT (1)
- Positron emission tomography (1)
- SLAMF7 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- abnormalities (1)
- adverse events (1)
- artificial intelligence (1)
- autologous transplantation (1)
- biosynthesis (1)
- bone marrow cells (1)
- bone remineralization (1)
- calcium imaging (1)
- cancer (1)
- cardiac transplantation (1)
- cell staining (1)
- cells (1)
- chemokine receptor (1)
- combination therapy (1)
- computed tomography (1)
- death rates (1)
- deletion 17P (1)
- depression (1)
- diagnostic medicine (1)
- elotuzumab (1)
- esophagogastric junction (1)
- experience (1)
- growth-factor receptor 3 (1)
- high-risk cytogenetics (1)
- imaging techniques (1)
- in vivo imaging (1)
- induction regimen (1)
- intergroupe francophone (1)
- involvement (1)
- kidney (1)
- lenalidomide-refractory patients (1)
- lesions (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- myeloma (1)
- natural language processing (1)
- newly diagnosed (1)
- observational (1)
- ontology (1)
- participation in clinical trials (1)
- plus dexamethasone (1)
- quality of life (1)
- radionuclide therapy (1)
- rare SNP (1)
- real world evidence (1)
- receptor tyrosine kinases (1)
- regression analysis (1)
- renal failure (1)
- safety (1)
- stem cell transplantation (1)
- survival (1)
- therapy (1)
- translocation (1)
- treatment response (1)
- whole-body imaging (1)
Institute
- Medizinische Klinik und Poliklinik II (18)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Pathologisches Institut (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Medizinische Klinik und Poliklinik I (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Humangenetik (1)
- Institut für Informatik (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
Sonstige beteiligte Institutionen
Background: Therapy for multiple myeloma (MM) has substantially improved in the era of immunomodulatory drugs and bortezomib. However, the prognosis of patients with progressive disease despite treatment with these ‘novel agents' remains poor. Recently, pomalidomide was approved in this setting, but a median progression-free survival of <4 months still leaves room for improvement. Pomalidomide-based combination therapies are currently under investigation, but data on long-term treatment are lacking. Case Report: We present the case of a 68-year-old woman with refractory MM who received pomalidomide in combination with various drugs including anthracyclines, alkylators and proteasome inhibitors. Initially, major hematological toxicities and infectious complications including a hepatitis B virus reactivation were encountered. With careful dose adjustments and selection of combination partners, pomalidomide treatment was maintained for over 4 years and led to a sustained partial remission. In particular, the well-tolerated regimen of bortezomib, cyclophosphamide and dexamethasone together with pomalidomide was administered for >30 cycles. Conclusion: This case illustrates the value of an individualized approach to myeloma care given an increasing availability of ‘novel agents'. Tailored treatment using these drugs as a backbone is essential to achieve long-lasting responses and minimize side effects.